Theme: Exploring the novel research and innovations in Cell & gene therapy

Cell Therapy 2017
Past Report of Cell Therapy-2015

Cell Therapy 2017

Sessions/Tracks

Track-1 Cell Therapy:

Cell therapy market investigation gives information about generally accepted clinical and analytical methods that are currently in use for applying cell therapy techniques. It is mainly used mainly in clinics and hospitals. Analysis is done on those companies and products that are actively developing and marketing instrumentation, reagents, and supplies for cell therapy. The cell-based research markets was analysed for 2015, and projected to 2025.They analysed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell ResearchOrlando, USA, March 20-22, 2017; 15th World Congress on Biotechnology and Biotech Industries Meet, Rome, Italy, March 20-21,2017; 2nd International Conference on Genetic Counselling and Genomic Medicine , Beijing, China,July 10-12, 2017; International Conference on Clinical and Molecular Genetics, Las Vegas, USA, April 24-26, 2017.

 

Track-2 Cellular Therapy Technologies:

Cell therapy technologies overlap with those of gene therapy,immune therapy cancer vaccines, drug delivery, drug discovery, tissue engineering and regenerative medicine. The cellular therapy technologies and methods, which have already started to play a very important role in the practice of medicine. Cell treatments and immunotherapies are changing the substance of pharmaceutical, empowering specialists, doctors and researchers to address the side effects of a sickness, as well as its basic causes, basically educating the body to recuperate itself. The pace of current advancements in cell treatment and immunotherapy is promising, with a few scientists reporting remarkable clinical results.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

2nd International Conference on Molecular Biology , London, UK , June 22-24, 20173rd World Bio Summit & Expo, Abu Dhabi, UAE, June 19-21, 20175th International Conference on Integrative Biology, London, UK, June 19-21, 20172nd World Congress on Human Genetics, Chicago, USA, July 24-26, 20179th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017.

 

Track-3 Cell Therapy of Cardiovascular Disorders

Cardiovascular disease implies a range of disease entities whose therapeutic actions differ. Cell therapy is a 21st century approach which is used to treating the cardiovascular disease and now it is being applied worldwide. However, no concerted approach exists for defining the best treatment conditions.Cardio vascular disorders  remains the number one cause of morbidity and mortality in the United States and Europe. In the United States alone, ≈1 million patients are suffering with myocardial infarction every year, with an associated mortality of 26% at 3 years.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

2nd Biotechnology World Convention, London, UK, May 25-27, 2017;  International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017; 9th International Conference on Cancer Genomics, Chicago, USA, May 29-31, 2017; 6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell Research, Orlando, USA, March 20-22, 2017.

 

Track-4 Cell Therapy for Cancer

A number of cell and gene therapy strategies are being evaluated in patients suffering from cancer and these include manipulating cells to gain or lose function. Clinical trials of cell therapy for many different cancers are currently ongoing.  The scientists has recently  developed novel cancer therapies by combining both gene and cell therapies. Cancer therapeutics cannot cure cancer and yet in 2014, the overall market for Oncologic therapeutics stood at about $84.3 billion. Any drug that can treat a reasonable survival of more than five years for cancer patients can achieve a blockbuster status. Within oncologic therapeutics, immunotherapeutic drugs have increased worldwide acceptance, because they are targeted drugs targeting only cancer cells.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

15th World Congress on Biotechnology and Biotech Industries Meet ,Rome, Italy,March 20-21, 2017 2nd International Conference on Genetic Counselling and Genomic Medicine ,Beijing, China, July 10-12, 2017;  International Conference on Clinical and Molecular Genetics, Las Vegas, USA, April 24-26, 2017; 15th Euro Biotechnology Congress, Valencia, Spain, June 05-07, 2017; International Conference on Integrative Medicine & Nutrition, Dubai, UAE, May11-13, 2017.

 

Track-5 Cell Therapy for Neurological Disorders

New visions into the biology of neural stem cells (NSCs) have raised expectations for their use in the treatment of neurologic diseases. The truth is that the field is moving forward every year, well thought out clinical trials are being planned and undertaken, but to date none have shown  a level of effectiveness that gives hope they may be useful as mainline therapies in 2013. With period, development will be made, but it is only by following the well-established methods of transformation from the laboratory to the clinic that this can happen. If such approaches are abandoned in the rush to get to clinic, then there is a real risk that the whole field will be derailed by a terrible result of an ill thought out treatment. If this were to happen then those treatments being advanced using sound scientific principles and which promise to be of a great use in the future, will instead be lost forever as the unproven, commercially driven cells of today confuse and kill the field. Cell therapy and gene transfer to the diseased or injured brain have provided the basis for the development of potentially powerful new therapeutic strategies for a broad spectrum of human neurological diseases.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell ResearchOrlando, USA, March 20-22, 2017; 15th World Congress on Biotechnology and Biotech Industries Meet, Rome, Italy, March 20-21,2017; 2nd International Conference on Genetic Counselling and Genomic Medicine , Beijing, China,July 10-12, 2017; International Conference on Clinical and Molecular Genetics, Las Vegas, USA, April 24-26, 2017.

 

Track-6 Cell Science & Stem Cell Research

Stem cell technology is the subject of much discussion and interest across the world. Newspapers and websites frequently report new discoveries, and this fast-paced field has been the focus of hope, excitement and sometimes controversy. Policy makers, regulators, researchers,clinicians and scientists are constantly debating the progress and potential applications of this exciting science. This Stem cell global  strategic report will help us to understand unique product opportunities by stem cell type, derive more revenue from products sold to stem cell scientists, and identify new product growth opportunities before the competition. Use the Survey of Stem Cell Scientists & researchers to understand technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

3rd International Conference on Synthetic Biology, Munich, Germany, July 20-21, 2017;  International Conference on Integrative Medicine & Nutrition, Dubai, UAE, May11-13, 2017; International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017; International Conference on Cell Signalling and Cancer Therapy, Paris, France,Aug 20-22, 2017; 9th Annual Conference on Stem Cell and Regenerative Medicine, Berlin, Germany, Sep 25-26, 2017.

 

Track-7 Cell Culture & Bioprocessing

Getting cell therapy products onto the market as quickly as possible still remains a key driver in the improve of recombinant therapeutic proteins. Any such advance in bioprocessing is of particular interest to the industry if it considerably shortens the development timeline or improves the end product. In the monoclonal antibody (MAb) area, platform procedures have allowed companies to regulate on particular mammalian cell lines, transfection approaches, process conditions and also downstream processing to shorten the development timeline.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017; 7th International Conference on Plant Genomics, Bangkong,Thailand, July 03-05, 2017; International Conference on Integrative Medicine & Nutrition, Dubai, UAE, May11-13, 2017; 14th Asia-Pacific Biotech Congress, Beijing,China, April 10-12, 2017;  2nd World Congress on Human Genetics, Chicago, USA, July 24-26, 2017.

 

Track-8 Cell Line Development

The global cell line growth development in the market is segmented on the basis of products, types of cell lines used, the source of cell lines, applications, and geographies. The global cell line development market size was valued at USD 2.38 billion in 2014. The key growth drivers include the increasing demand for monoclonal antibodies, raising demand for effective cancer treatments and technical advancements introduced in this field. The global cell line growth market size was valued at USD 2.38 billion in 2014. Key growth drivers include the rising demand for monoclonal antibodies, raising demand for effective cancer therapeutics and technical advancements introduced in this field.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

15th World Congress on Biotechnology and Biotech Industries Meet ,Rome, Italy, March 20-21, 2017;  6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell Research, Orlando, USA, March 20-22, 2017;  14th Asia-Pacific Biotech Congress, Beijing, China, April 10-12, 2017;  5th International Conference on Integrative Biology, London, UK, June 19-21, 2017.

 

Track-9 Tissue Science & Regenerative Medicine:

The Global Tissue Science & Regenerative Medicine Market is estimated to observe the highest development coming from the Tissue Engineering segment. By technology type, biomaterial segment presently holds the largest market share of global regenerative medicine market. However, Tissue Engineering segment is expected to be the fastest growing segment over the forecast period. In terms of value, the tissue engineering segment market is anticipated to increase at an outstanding CAGR of 17.5% over the forecast period of 2015-2019, to reach a market value of about US$ 1,070 Mn by 2019. Currently, it accounts for almost 13.2% of the total share of the global regenerative medicine market, which is expected to increase growth potentially by 2019 end.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

3rd International Conference on Synthetic Biology, Munich, Germany, July 20-21, 2017; 5th International Conference and Exhibition on Cell and Gene Therapy,Madrid, Spain, Mar 2-3, 2017;  International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017;  9th International Conference on Cancer Genomics, Chicago, USA, May 29-31, 2017;  14th Asia-Pacific Biotech Congress, Beijing, China, April 10-12, 2017.

 

Track-10 Gene Therapy

Currently, the concept of gene therapy is being authorized by numerous pharmaceutical companies using clinical data, and there is a increasing interest among venture capitalists to discover the commercial potential of gene therapy. However, the development of the gene therapy market is largely needy on the regulatory environment, and on approvals from industry bodies. Currently, most gene therapy products are still in the clinical trials phase II and phase III, of which a common focuses on the treatment of oncology and heart diseases. The growing popularity of DNA vaccines has positively impacted the development of this market, and there is a high chance of cell and gene therapy being practiced in clinics in the next few years, as encouraging results are developing from the phase II/III trials. Gene therapies market will generate $204m in 2020, according to new visiongain analysis

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

2nd World Congress on Human Genetics, Chicago, USA, July 24-26, 2017; 2nd International Conference on Genetic Counselling and Genomic Medicine ,Beijing, China, July 10-12, 2017;  International Conference on Clinical and Molecular Genetics, Las Vegas, USA, April 24-26, 2017; 2nd International Conference on Molecular Biology ,London, UK, June 22-24, 2017; 15th Biotechnology Congress, Baltimore, USA, June 22-23, 2017.

 

Track-11 Cancer Gene Therapy

Initially, scientists followed gene therapy for the administration of genetic material to treat genetic disorders, and it was soon adapted for cancer treatment. Approximately two-thirds of the clinical trials in gene therapy have been designed at the treatment of various types of cancers.  Cancer Gene Therapy Market size was USD 805.5 million in 2015, with 20.7% CAGR estimation from 2016 to 2024; as per a new global strategic research report. Globally, increasing cancer prevalence will rise demand for gene therapy as the effective personalized treatment choice.  According to WHO, cancer incidence is estimated to rise by 50% to reach 15 million by the end of this decade. This  increase in number of patients needs this as a potential treatment approach addressing the growing global burden of the disease.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell Research, Orlando, USA, March 20-22, 2017; 15th World Congress on Biotechnology and Biotech Industries Meet, Rome, Italy, March 20-21, 2017; 2nd International Conference on Genetic Counselling and Genomic Medicine , Beijing, China, July 10-12, 2017; International Conference on Clinical and Molecular Genetics, las vegas, USA, April 24-26, 2017.

 

Track-12  Diabetis Gene Therapy

Recent developments in the field of molecular and cell biology may allow for the growth of novel strategies for the therapy and cure of type 1 diabetes. In particular, it is now possible to predict restoration of insulin secretion by gene or cell-replacement therapy. Diabetes mellitus is growing globally affecting more than 180 million people worldwide . This is mostly type 2 diabetes and, because of the growth in the aging population and massive increase in prevalence of obesity, the incidence is likely to be more than doubled by 2030.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

15th Biotechnology Congress, Baltimore, USA, June 22-23, 2017; 3rd International Conference on Synthetic Biology, Munich, Germany, July 20-21, 2017; 5th International Conference and Exhibition on Cell and Gene Therapy, Madrid, Spain, Mar 2-3, 2017;  International Conference on Cell Signalling and Cancer Therapy, paris, France, Aug 20-22, 2017;  International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017.

 

Track-13 Vectors for Gene Therapy

According to the new research Global  strategic report Gene Therapy Market Forecast to 2020, a major focus has been on the on-going clinical trials for the growth of innovative products using different vectors. Increasing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new therapy modalities to help make cancer a manageable disease. By the end of 2012, the expected number of clinical trials crossed 1,800 worldwide.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017; 7th International Conference on Plant Genomics, Bangkok, Thailand, July 03-05, 2017; 15th Euro Biotechnology Congress, Valencia, Spain, June 05-07, 2017; 5th International Conference and Exhibition on Cell and Gene Therapy, Madrid, Spain, Mar 2-3, 2017; 3rd International Conference & Exhibition on Tissue Preservation and Bio banking, Baltimore, USA, June 29-30, 2017.

 

Track-14  Molecular Epigenetics

The global Epigenetic strategic research market was valued at an estimated $413.24 Million in 2014. This market is expected to ncrease at a CAGR of 13.64% between 2014 and 2019 to reach $783.17 Million in 2019. This Market is segmented mainly on the basis of products into enzymes; instruments and consumables; kits; and reagents. Each of these market is further divided into multiple product segments and sub-segments.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017; 14th Asia-Pacific Biotech Congress, Beijing, China, April 10-12, 2017; 15th Biotechnology Congress, Baltimore, USA, June 22-23, 2017; 3rd International Conference on Synthetic Biology, Munich, Germany,July 20-21, 2017; 5th International Conference and Exhibition on  Cell and Gene TherapyMadrid, Spain, Mar 2-3, 2017.

 

Track-15  Genetics & Genomic Medicine

The National Human Genome Research Institute describes genomic medicine as "an developing medical discipline that mainly involves using genomic information about an individual as part of their clinical care (e.g., for diagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Geographically, the global Genomic Medicine market is classified into different regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of huge number of academic as well as research institutions in the United States. which are mainly working on genomic medicine to discover next-generation genomic medicines, North America region is expected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several academies offering educational programs coupled with openings in scientific research  in the North America and Europe is expected to have positive impact on the regional markets. The genetic & genomic medicine concept still in its nascent stage is yet to receive an drive from the emerging market which are anticipated to hold smaller shares in the global market.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th Annual Conference on Stem Cell and Regenerative Medicine ,Berlin, Germany, Aug 04-05, 2016;  2nd Biotechnology World Convention,London,, UK, May 25-27, 2017; International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017; 9th International Conference on Cancer Genomics, Chicago, USA, May 29-31, 2017;  3rd International Conference on Synthetic Biology, Munich, Germany, July 20-21, 2017.

 

Track 16 Gene Therapy Commercialization

The major theme of this  is whether gene therapy can attain commercial success by the early-to-mid 2020s, which types of gene therapy programs have the greatest likelihood of success, and what hurdles might stand in the way of clinical and commercial success of leading gene therapy programs. Asynchrony between the maturation of gene therapy technologies and capital investment in development-focused business models may have stalled the commercialization of gene therapy.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

Track 17 Gene Therapy for rare & Common Diseases

Gene therapy is a logical way to treat rare genetic disorders; and cure a single gene defect by introducing with a 'correct' gene. The first gene-therapy trials were conducted using patients with rare monogenetic disorders, but these are now outstripped by the clinical testing of gene therapeutics for more common conditions, for ex: cancer, AIDS and heart disease. This is partially due to a failure to achieve long-term gene expression with early vector systems, a critical condition for correcting many inborn genetic defects. 

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell Research, Orlando, USA, March 20-22, 2017; 15th World Congress on Biotechnology and Biotech Industries Meet, Rome, Italy, March 20-21, 2017; 2nd International Conference on Genetic Counselling and Genomic Medicine , Beijing, China, July 10-12, 2017; International Conference on Clinical and Molecular Genetics, las vegas, USA, April 24-26, 2017.

 

Track 18 Gene Editing Technology

The genome editing market is expected to reach USD 5.54 billion by 2021 from USD 2.84 Billion in 2016, and it wil grow  at a CAGR of 14.3% in the next five years (2016 to 2021). The growth of the overall market can be accredited to factors such as increasing government funding and growth in the number of genomics projects, high prevalence rate of infectious diseases and cancer among patients, technological advancements, increasing demand for synthetic genes, growing awareness about genomics, and increasing new product launches by industry players are expected to drive the market in the coming years. Rise in the production of genetically modified crops is also expected to increase the demand for genome editing.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017; 7th International Conference on Plant Genomics, Bangkok, Thailand, July 03-05, 2017; 15th Euro Biotechnology Congress, Valencia, Spain, June 05-07, 2017; 5th International Conference and Exhibition on Cell and Gene Therapy, Madrid, Spain, Mar 2-3, 2017; 3rd International Conference & Exhibition on Tissue Preservation and Bio banking, Baltimore, USA, June 29-30, 2017.

 

 Track 19 Cell & Gene Therapy Products

The Center for Biologics Evaluation and Research (CBER) controls cellular and gene therapy products and certain devices related to cell and gene therapy.  In addition to regulatory oversight of clinical studies, it also provides proactive scientific and supervisory advice to medical and clinical researchers and manufacturers in the area of novel product development.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

International Conference on Animal and Human Cell Culture, Jackson Ville, USA, Sep 25-27, 2017; 14th Asia-Pacific Biotech Congress, Beijing, China, April 10-12, 2017; 15th Biotechnology Congress, Baltimore, USA, June 22-23, 2017; 3rd International Conference on Synthetic Biology, Munich, Germany,July 20-21, 2017; 5th International Conference and Exhibition on  Cell and Gene TherapyMadrid, Spain, Mar 2-3, 2017.

 

Track 20 Ethical Issues in Cell & Gene Therapy

The use of human embryos for research on embryonic stem (ES) cells is currently top on the ethical and political agenda in many countries. Notwithstanding the potential benefit of using human Embryonic Stem cells in the treatment of diseases, their use remains controversial because of their origin from early embryos.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017; 7th International Conference on Plant Genomics, Bangkok, Thailand, July 03-05, 2017; 15th Euro Biotechnology Congress, Valencia, Spain, June 05-07, 2017; 5th International Conference and Exhibition on Cell and Gene Therapy, Madrid, Spain, Mar 2-3, 2017; 3rd International Conference & Exhibition on Tissue Preservation and Bio banking, Baltimore, USA, June 29-30, 2017.

 

Track 21 Regulatory & Safety  Aspects of  Cell & Gene Therapy

Cell therapy  products require a variety of safety considerations. Stem cell and gene  products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength  and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

5th International Conference on Integrative Biology, London, UK, June 19-21, 2017; 2nd World Congress on Human Genetics, Chicago, USA, July 24-26, 2017; 9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017;  International Conference on Integrative Medicine & Nutrition, Dubai, UAE, May11-13, 2017; 14th Asia-Pacific Biotech Congress,Beijing, China, April 10-12, 2017.

 

Track 22 Clinical Trails on Cell & Gen Therapy

Recent clinical trials of gene and cell therapy have shown remarkable therapeutically benefits and an excellent safety record. They provide evidence for the long-sought promise of gene and therapy to deliver 'cures' for some otherwise terminal disabling conditions. Behind these advances lie enhanced vector designs that enable the safe delivery of therapeutic genes to particular cells. Technologies for editing genes and modifying inherited mutations, the meeting of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight against cancer are also contributing to the regeneration of gene therapy.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

6th International Conference on Tissue Engineering & Regenerative Medicine, Baltimore, USA, Aug 20-22, 2017; 8th World Congress and Expo on Cell & Stem Cell Research, Orlando, USA, March 20-22, 2017; 15th World Congress on Biotechnology and Biotech Industries Meet, Rome, Italy, March 20-21, 2017; 2nd International Conference on Genetic Counselling and Genomic Medicine , Beijing, China, July 10-12, 2017; International Conference on Clinical and Molecular Genetics, Las Vegas, USA, April 24-26, 2017.

 

Track 23 Markets & Future Prospects for Cell  & Gene Therapy

The number of companies involved in cell therapy has improved remarkably during the past10 years. More than 550 companies have been identified and they particularly work on cell therapy. Of these companies, 170 are involved in stem cells. Profiles of 72 academic institutions paticularly in the US involved in cell and gene  therapy.

Related Cell Therapy | Gene Therapy | Cell Therapy Conferences | Gene Therapy Conferences | Conference Series LLC

9th International Conference on Genomics and Pharmacogenomics, Chicago, USA, July 13-14, 2017; 7th International Conference on Plant Genomics, Bangkong,Thailand, July 03-05, 2017; International Conference on Integrative Medicine & Nutrition, Dubai, UAE, May11-13, 2017; 14th Asia-Pacific Biotech Congress, Beijing,China, April 10-12, 2017;  2nd World Congress on Human Genetics, Chicago, USA, July 24-26, 2017.

 

 

 

 





About Conference

ConferenceSeries LLC welcomes you to attend the 6th International Conference and Exhibition on Cell & Gene Therapy during March 27-28, 2017 at Madrid,Spain. We cordially invite all the participants who are interested in sharing their knowledge and research in the arena of Cell & Gene Therapy.

Cell and Gene Therapy Conference is to ameliorate the knowledge, awareness, and education on cell and gene therapy leading to the discovery of genetic and cellular therapies which aid to alleviate the human disease as it is the most significant emerging technology in the eyes of Medical, Biotechnology, Pharmaceuticals and Academia. Cell and Gene Therapy Conference 2017 is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists.

Cell Therapy Conferences will provide a perfect platform to all the Doctors, Researchers Business Delegates and Scientists to approach and deliver all the attendees about the latest scientific advancements on the respective sphere.

Gene Therapy Conferences strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.

This two-day Gene Therapy Event will address key issues concerning cell and gene therapy in the broader context of cellular and genetic disorder. Organized around daily themes, the Conference focuses on moving from present knowledge to future solutions

Global markets for stem cells by BCC Research (2012), cited by Ministry of Food and Drug Safety, predicted the global market size of stem cell therapy product would be 6.6 billion dollars in 2016 and grow 11.7% on average every year. Currently, Europe cell therapy and gene therapy occupy share market of  872 million dollars. Europe's is 10.9% (1.5 billion dollars in 2016).

OMICS International Organises 300+ International Conferences Every Year across Europe,USA & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

The previous conferences on Cell & Gene Therapy which were held at San Antonio, USA and London, UK have explained Research & Advancements in Cell and Gene Therapy, gained so much of interest for eminent scientists all over the world in the field of Cell & Gene Therapy. Now it is the time for the 6th International Conference and Exhibition on Cell & Gene Therapy to address Exploring the novel research and innovations in Cell and Gene therapy  which will be held on March 2-3,2017 at Madrid, Spain.

Target Audience

Cell and Gene Therapy Students, Scientists

Cell and Gene Therapy Researchers

Cell and Gene Therapy Faculty

Cell and Gene Therapy Associations and Societies

Cell and Gene Therapy physicians

Cell and Gene Therapy advanced practice registered nurses,

Allied health professionals in the fields of Cell and Gene Therapy,hematology, oncology, neurology, family medicine and internal medicine.

Stem Cell Students, Scientists

Stem Cell Researchers

Stem Cell Faculty

Stem Cell Associations and Societies

Business Entrepreneurs

Training Institutes

Software developing companies









Past Conference Report

Cell Therapy 2016

OMICS International Conferences successfully hosted its premier 5th International Conference and Exhibition on Cell and Gene Therapy during May19-21, 2016 at Hilton San Antonio Airport, San Antonio, USA

 

The conference brought together a comprehensive range of the cell and gene therapy researchers, educators from research universities as well as representatives from industry and professional cell and gene therapy societies.

 

Cell Therapy-2016 is known for uplifting the future of cell and gene therapy and its allied areas by encouraging students and fellow researchers to present their work through poster presentations and young research forum. Students participated with great zeal and the best posters were awarded for their efforts and outstanding contribution to the cell and gene therapy research.

 

OMICS International Conferences wishes to acknowledge with its deep sincere gratitude to all the supporters from the Editorial Board Members of our Open Access Journals, Keynote speakers, Honourable guests, valuable speakers, poster presenters, students, delegates and special thanks to the media partners, Exhibitors for their promotion to make this event a huge success.

 

This 5th International Conference and Exhibition on Cell and Gene Therapy based on the theme “Frontiers in Cell and Gene Therapy: From Bench to Bedside” which covered the below scientific sessions like Gene Therapy, Cell and Gene Therapy Products, Cellular Therapy, Cancer Gene Therapy, Nano Therapy, Skin Cell Therapy, HIV Gene Therapy, Diabetes for Gene Therapy, Viral Gene Therapy, Stem Cell Therapies, Stem Cell Preservation, Stem Cell Products, Genetically Inherited diseases, Plant Stem Cells, Plant Stem Cell Rejuvenation, Clinical Trials in Cell & Gene Therapy, Molecular Epigenetics, Bioengineering Therapeutics, Advanced Gene Therapeutics, Ethical Issues of Therapies,.

 

The conference was greeted by the conference Moderator: Dr. Juliann G. Kiang, Uniformed Services University of The Health Sciences, USA. The support was extended by the Keynote Speaker: Dr. Vikas Kundra, MD Anderson Cancer Centre, USA; Dr. Jennifer Grinnell, Biosheprix, USA; Dr. Heidi Strona, PeproTech, USA

 

 

 

OMICS International acknowledges the support of below Chairs and Co-chairs with whom we were able to run the scientific sessions smoothly it included: Dr. Chan-Wha Kim, Korea University College of Life Sciences and biotechnology, Korea; Dr. Juliann G Kiang, Uniformed Services University of The Health Sciences, USA; Dr. Michail Ponizovskiy, Kiev regional p/n hospital, Germany.

 

This 5th International Conference and Exhibition on Cell and Gene Therapy was uplifted with more than 32 oral presentations by researchers, scientists, professors, industry delegates and more than 15 poster participants around the globe. OMICS International has taken the privilege of felicitating Cell Therapy-2016 Organizing Committee Members, Editorial Board Members of the supported Journals and Keynote Speakers who supported for the success of this event


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date Mar 27-28, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Media Partners

Conferenceseries Destinations